Resistance time of dabrafenib combined with trametinib

The time to resistance to dabrafenib and trametinib combination therapy varies between individuals and the type of cancer. Some studies have shown that in patients with malignant melanoma, the average resistance time is about 11-12 months. However, the duration of resistance may vary depending on the patient's condition, response to treatment, and other factors. The development of drug resistance is a common phenomenon that may lead to reduced or ineffective drug efficacy. Therefore, doctors typically monitor a patient's condition regularly and adjust treatment if needed. In addition, researchers are also working hard to find new treatment strategies to prolong the resistance time of combination therapy, such as combining other drugs or using new treatment methods. For patients, following their doctor's treatment recommendations, receiving regular medical monitoring and evaluation, and maintaining an active lifestyle are all important factors in prolonging treatment effects and improving survival rates.